Could taking drug breaks tame leukemia side effects?
NCT ID NCT03961672
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking duvelisib on an irregular schedule can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as the standard daily dosing, but with fewer severe side effects. Fifteen adults with cancer that returned or didn't respond to prior treatment are enrolled. The main goal is to see how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention
- Stem cell transplant study seeks best way to prevent immune attack
- New Two-Step transplant shows promise for blood cancer patients